Literature DB >> 17657202

The role of (124)I-PET in diagnosis and treatment of thyroid carcinoma.

M Lubberink1, S Abdul Fatah, B Brans, O S Hoekstra, G J J Teule.   

Abstract

Iodine-124 is a positron-emitting iodine isotope, enabling measurement of iodine uptake using positron emission tomography (PET). There is a number of situations where the use of (124)I-PET/computed tomography (CT) can improve the current clinical practice in the diagnosis and treatment of thyroid cancer. Firstly, (124)I-PET/CT can aid in the staging of patients, because of better detection of metastatic disease and measurement of metabolic tumour volume, and thus separate low-risk from high risk patients. Secondly, the much higher sensitivity and spatial resolution of PET compared to gamma scintigraphy can also improve detection of recurrent disease. Furthermore, (124)I-PET can be used for patient-specific radioiodine therapy radiation dosimetry. Simultaneous administration of the therapeutic dose of (131)I and a tracer dose of (124)I allows for accurate measurement of iodine uptake during therapy. The decay scheme of (124)I, with few positrons and many gamma rays emitted per decay, often simultaneously, poses a challenge to quantitative PET imaging. Improved correction methods and the use of last-generation PET/CT scanners with faster electronics and better energy resolution can overcome this.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17657202

Source DB:  PubMed          Journal:  Q J Nucl Med Mol Imaging        ISSN: 1824-4785            Impact factor:   2.346


  6 in total

Review 1.  Changing Paradigm in Treatment of Differentiated Thyroid Cancer.

Authors:  Krishna B A; Mohammed Saleel K
Journal:  Indian J Surg Oncol       Date:  2022-03-22

2.  Pre-therapeutic (124)I PET(/CT) dosimetry confirms low average absorbed doses per administered (131)I activity to the salivary glands in radioiodine therapy of differentiated thyroid cancer.

Authors:  Walter Jentzen; Robert F Hobbs; Alexander Stahl; Jochen Knust; George Sgouros; Andreas Bockisch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-01-13       Impact factor: 9.236

3.  False-positive uptake on radioiodine whole-body scintigraphy: physiologic and pathologic variants unrelated to thyroid cancer.

Authors:  Jong-Ryool Oh; Byeong-Cheol Ahn
Journal:  Am J Nucl Med Mol Imaging       Date:  2012-07-10

4.  Recurrent differentiated thyroid cancer: towards personalized treatment based on evaluation of tumor characteristics with PET (THYROPET Study): study protocol of a multicenter observational cohort study.

Authors:  Jakob W Kist; Bart de Keizer; Marcel P M Stokkel; Otto S Hoekstra; Wouter V Vogel
Journal:  BMC Cancer       Date:  2014-06-05       Impact factor: 4.430

5.  I-124 Imaging and Dosimetry.

Authors:  Russ Kuker; Manuel Sztejnberg; Seza Gulec
Journal:  Mol Imaging Radionucl Ther       Date:  2017-02-09

6.  Effectiveness of [(124)I]-PET/CT and [(18)F]-FDG-PET/CT for localizing recurrence in patients with differentiated thyroid carcinoma.

Authors:  Jandee Lee; Kuk Young Nah; Ra Mi Kim; Yeon-Ju Oh; Young-Sil An; Joon-Kee Yoon; Gwang Il An; Tae Hyun Choi; Gi Jeong Cheon; Euy-Young Soh; Woong Youn Chung
Journal:  J Korean Med Sci       Date:  2012-08-22       Impact factor: 2.153

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.